CGT Catapult appoints two new Board members
Published on 27 Oct 2020
Stevenage named High Potential Opportunity zone for Cell and Gene Therapy
Published on 12 Oct 2020
Stevenage Bioscience Catalyst opens Spark Building to support Cell and Gene scale-up
Published on 12 Oct 2020
Press Release: CGT Catapult appoints Dr Nick Johnson as Chief Strategy and Impact Officer
Published on 6 Oct 2020
LifeArc and UK government’s Future Fund provide £3.0m in funding to Avvinity Therapeutics to drive development of new cancer therapies
Published on 23 Sep 2020
Immune Regulation Limited raises £40.6 million / $53.4 million Series B Equity Financing
Published on 21 Sep 2020
AKL Research & Development’s novel osteoarthritis medicine APPA begins Phase II trial with partner Nordic Bioscience Clinical Development
Published on 18 Sep 2020
CombiGene and CGT Catapult collaboration completes development of quality control analytical assays for clinical production of CombiGene’s AAV-based gene therapy for the treatment of epilepsy
Published on 17 Sep 2020
Gyroscope Therapeutics Announces FDA Clearance For Orbit Subretinal Delivery System
Published on 27 Aug 2020

Peptinnovate announces change of name to Immune Regulation, strengthening of the Board and successful fundraise

Read the article
The appointment of these three experienced industry executives will bring valuable insight and resource to our Board and executive team. With their skills in immunology, clinical therapeutic development and strategy we have the expertise to advance our clinical programmes and look forward to the next stage of our progress.
Prof. Clive Page
Chairman of Immune Regulation
ReViral Raises $44 Million in Series C Financing
Published on 25 Aug 2020
Gyroscope Therapeutics Announces Initiation Of Phase II Programme Evaluating Its Investigational Gene Therapy, GT005, for Dry Age-related Macular Degeneration
Published on 25 Aug 2020
Stevenage Bioscience Catalyst announces Professor Jackie Hunter as new Chair
Published on 17 Aug 2020
Freeline Announces Pricing of Initial Public Offering
Published on 14 Aug 2020
Bayer to acquire UK-based biotech KaNDy Therapeutics Ltd.
Published on 11 Aug 2020
LifeArc appoints Dr Ian Campbell as Chief Business Officer
Published on 31 Jul 2020
AKL Research and Development partner with world-leading animal health company to test novel osteoarthritis drug in dogs
Published on 29 Jul 2020
TCR² Therapeutics Announces Recist Responses With First Tc-210 Dose Tested In Advanced Mesothelin-expressing Solid Tumors
Published on 27 Jul 2020
Press release: CPI, the Cell and Gene Therapy Catapult and MicrofluidX announce development of technology to rapidly scale up cell and gene therapy manufacture
Published on 27 Jul 2020
Press Release: Over £100m cash boost to manufacture millions of doses of COVID-19 vaccine
Published on 23 Jul 2020
UCLB and Apollo Therapeutics secure first out-licensing deal to Deerfield, a leading U.S. healthcare investment firm
Published on 23 Jul 2020
Annual Review 2020 highlights impact on growth and productivity in the UK cell and gene therapy industry
Published on 20 Jul 2020

Copyright © 2020 Stevenage Bioscience Catalyst

Designed and built by Onespacemedia

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.